Based on the aggregated intelligence of 115,000 investors participating in Motley Fool CAPS, the Fool's free investing community, Chinese medical-device maker Mindray Medical (NYSE:MR) has earned a coveted five-star ranking. Our data has shown that five-star stocks outperform the market by a significant margin; conversely, one-star stocks have woefully lagged the market average.

With that in mind, let's take a closer look at Mindray's business, and see what CAPS investors are saying about the stock right now.

Mindray facts


Shenzhen, China (1999)

Market Cap

$3.0 billion


Health-Care Equipment

TTM Revenue

$431 million


Co-Founder/Co-CEO Hang Xu

Co-Founder/Co-CEO Xiting Li

Return on Capital (average last two years)



Abbott Labs (NYSE:ABT)

Koninklijke Philips Electronics (NYSE:PHG)

CAPS members bullish on MR also bullish on

Suntech Power (NYSE:STP) (NASDAQ:CTRP)

CAPS members bearish on MR also bearish on

ChinaMobile (NYSE:CHL)

First Solar (NASDAQ:FSLR)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, some 95% of the 227 All-Star members who have rated Mindray believe the stock will outperform the S&P 500 going forward. These All-Star bulls include cptsintl and pennysplants, both of whom are ranked in the top 5% of our community.

In May, cptsintl wrote that Mindray is "Quickly developing into one of the largest medical technology companies in World. Based in China, its potential is remarkable."

An earlier pitch from pennysplants shares that sentiment, indicating that some significant progress is just beginning to become visible:

[Competitive] advantages, dedication to R&D, BOTH Chinese and international markets / sales force, stellar management (all things considered), good balance sheet/financial health, and in a sector which is growing by leaps and bounds (tho margins may decline)... Yes, things may stagnate here for a while during the DataScope integration, but I can wait til '09 for increased earnings and cross-selling to become accretive. Analysts are saying 40-45% annual eps growth. I'd settle for 25% with a company of this quality and in this sector.

What do you think about Mindray, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 115,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Mindray Medical and Suntech are Rule Breakers picks. is a Motley Fool Hidden Gems selection. The Fool's disclosure policy always gets a perfect score.